http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012121767-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07a620aa7ffa965c6bddb794889b2e33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3765620e50769cb1d8f3eb6befdea1a9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0039 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0092 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F6-14 |
| filingDate | 2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d729486a0eb5054d50d631c0b9cd5a34 |
| publicationDate | 2012-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012121767-A1 |
| titleOfInvention | Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent |
| abstract | The present invention relates to the reduction in the size of uterine fibroids or uterus by intravaginal administration of low doses of selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent. According to the present invention, the active drug (i.e., SPRM, anti-progestin, or anti-progestational agent) is delivered directly to the affected tissue(s), particularly the uterine fibroids that are close to the vagina where the delivery device (e.g., vaginal ring or IUD) is placed. As specified herein, effective local concentrations of drug are achievable with doses much lower than those administered by the oral route. When used according to the method of the invention, levels of the SPRM (or anti-progestin, or anti-progestational agent) in systemic circulation are greatly reduced as compared to oral therapies, possibly below detectable limits, leading to a lower incidence of adverse events. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015535282-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104755087-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10328022-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014070517-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9545411-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013338305-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015320766-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015297612-A1 |
| priorityDate | 2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.